STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1769 by analyst upside · 2026-06-27
PHVS
Pharvaris N.V.
Healthcare · Market Cap $2B · P/E 0x
ANALYST PRICE TARGET
+35.6%
implied upside to consensus target
Current Price $34.01
Consensus Target $46.12
Bull Target $71.88
Bear Target $32.1
Analysts Covering 13
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
9
Hold
1
Sell
0
52-Week Low $16.72
52-Week High $35.33
YTD Return +28.4%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) N/A
Forward P/E -12.9x
EPS (TTM) $-3.09
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $16.72
52-Week High $35.33
Current Price $34.01
Bear Target $32.1
Bull Target $71.88
● Now $34.01 ● Target $46.12
TRADING DATA
Avg Volume 332K
YTD Return +28.4%
Analyst Count 13
Consensus Buy
Upside to Target +35.6%
Last Updated 2026-06-27

ANALYST SUMMARY

Pharvaris N.V. (PHVS) is currently trading at $34.01 with a Wall Street consensus price target of $46.12, implying potential upside of 35.6% over the next 12 months. 13 analysts currently cover PHVS, with a consensus rating of Buy - 92% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $71.88, while the most cautious has a target of $32.1.

PHVS operates in the Healthcare sector with a market capitalisation of $2B. The stock is up 28.4% year-to-date and is currently trading near the upper end of its 52-week range of $16.72 – $35.33.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for PHVS, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Citizens — Reiterated
Market Outperform → Market Outperform 2026-05-13 Building track record
Wolfe Research ● Initiated
Outperform 2026-04-09 Building track record
Wedbush — Reiterated
Outperform → Outperform 2026-04-07 Building track record
RBC Capital — Reiterated
Outperform → Outperform 2026-04-06 Building track record
RBC Capital ● Initiated
Outperform 2026-03-09 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-03-03 31% win rate (48 calls)
Oppenheimer — Reiterated
Outperform → Outperform 2025-12-04 14% win rate (7 calls)
Guggenheim — Reiterated
Buy → Buy 2025-12-04 62% win rate (8 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
49
out of 100
Coverage depth
20/30
Consensus clarity
7/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →